Baxter 1Q12

1Q Revenues: $3.4 billion (+3%)

1Q Earnings: $588 million (+3%)

Comments: BioScience revenues grew 4% to $1.5 billion, driven by demand for Advate and Gammagard Liquid, while the Medical Products business was up 3% to $1.9 billion. In the BioScience unit, recombinants rose 4% to $533 million, antibody therapies were up 4% to $388 million, plasma proteins were up 3% to $316 million and regenerative medicine was up 10% to $154 million.